past events
- 2015-
- The 3rd Annual ASA NJ Chapter/Bayer Statistics Workshop
- Evaluating the Validity of Network Meta-Analyses
- Meta-analysis of rare events in drug safety studies: An unifying framework for exact inference
- A Bayesian hierarchical surrogate outcome model for multiple sclerosis
- Integrated Data Analysis for Assessing Treatment Effect through Combining Information from All Sources
- ASA NJ Chapter 36th Annual Spring Symposium
- Reflections on the Opportunities and Challenges of Big Data- Demissie Alemayehu, Pfizer
- Taking Biostatistics to New Dimensions- Dhammika Amaratunga, Independent Statistical Consultant, ASA Fellow
- Real World Data: How It’s Used at a Medical Device Company- Myoung Kim and Andrew Yoo, J & J
- Analytical Approaches for Characterizing the Diffusion of New Medical Technologies- Sharon-Lise Normand, Harvard
- Likelihood Ratio-based Tests for Signal Detection from Large Drug Safety Databases- Ram Tiwari, FDA
- The 3rd Annual ASA NJ Chapter/Bayer Statistics Workshop
- 2014-
- The 2nd Annual ASA NJ Chapter/Bayer Statistics Workshop
- Intention-to-Treat Analysis in Clinical Trials with Treatment Discontinuation and Missing Data-Roderick Little, University of Michigan
- Missing Data Sensitivity Analysis of Continuous Endpoint, An Example from a Recent Submission-Arno Fritsch, clinical Statistics Europe, Bayer
- Missing Data for Rivaroxaban-Xiang Sun, Janseen Research and Development LLC of J & J
- Multiple Imputation Method for Sensitivity Analysis of Time-to-Event Data with Possible Informative Censoring-Yue Zhao, Merck
- ASA NJ Chapter 35th Annual Spring Symposium
- Bayesian Evidence Synthesis in Drug Development and Comparative Effectiveness Research-David Ohlssen, Novartis
- Generalizing the MCPMod Methodology beyond Normal, Independent Data-José Pinheiro, Janssen Research & Development
- Modeling & Simulation to Improve the Design of Clinical Trials-Gary L. Rosner, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Meta-analysis of Clinical Dose Response in a Large Drug Development Portfolio-N. Thomas, Pfizer
- Integration of Knowledge from Late Phase Trials to Support Regulatory Decisions-Yaning Wang, FDA
- The 2nd Annual ASA NJ Chapter/Bayer Statistics Workshop
- 2013-
- Bayer / ASA NJ Chapter Benefit-Risk Workshop
- Examining Benefit and Risk Simultaneously at the Individual Patient Level, Christy Chuang-Stein
- A Case Study using the BRAT Framework and Quantitative Methods for Benefit-Risk Assessment, Chistoph Dierig
- Pragmatic Considerations for Endpoint Selection and Display in Cardiovascular Benefit-Risk Assessment, Bennett Levitan
- ASA NJ Chapter Complimentary Symposium on Patient Reported Outcomes
- ASA NJ Chapter 34th Annual Spring Symposium
- Bayer / ASA NJ Chapter Benefit-Risk Workshop
- 2012-
program
- Comparative effectiveness of dynamic treatment regimes, Miguel Hernán
- Covariate Balancing Propensity Score, Kosuke Imai
- Strategies for Using Partially Valid Instrumental Variables, Dylan Small
- Compliance Mixture Modelling with a Zero Effect Complier Class and Missing Data, Michael E. Sobel
- Exploring New Statistical Methods for Causal Inference in Longitudinal Studies, Zhiqiang Tan